Site icon pharmaceutical daily

Infliximab Biosimilars Insight Report, 2020 – Comprehensive Insights of 35+ Companies and 45+ Marketed and Pipeline Drugs – ResearchAndMarkets.com

BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Infliximab – Biosimilars Insight, 2020” report has been added to ResearchAndMarkets.com’s offering.

This Infliximab- Biosimilar Insight, 2020 report provides comprehensive insights of 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Infliximab Understanding

Infliximab: Overview

Infliximab, a chimeric monoclonal antibody, sold under the brand name Remicade among others, is a medication used to treat a number of autoimmune diseases. This includes Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, and Behet’s disease. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-) is a key proinflammatory cytokine involved in chronic inflammatory diseases.

Its hyperactivity and enhanced signalling pathways can be observed in inflammatory diseases where it activates further pro-inflammatory cascades. By binding to both the soluble subunit and the membrane-bound precursor of TNF- 1, infliximab disrupts the interaction of TNF- with its receptors and may also cause lysis of cells that produce TNF- 1

Infliximab Biosimilars: Drugs Chapters

This segment of the Infliximab report encloses its detailed analysis of various drugs in different stages of clinical development, including marketed, phase III, II, I and preclinical. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases. (Read more…)

Infliximab Biosimilars: Marketed Drugs

Inflectra: Celltrion/Pfizer

Inflectra will be the first biosimilar monoclonal antibody (mAb) and only the second biosimilar to be available in the U.S. It is approved for the treatment of: adult patients and pediatric patients (ages six years and older) with moderate to severely active Crohn’s disease who have had an inadequate response to conventional therapy;adult patients with moderate to severely active ulcerative colitis who have had an inadequate response to conventional therapy; and moderate to severely active rheumatoid arthritis in combination with methotrexate; active ankylosing spondylitis; active psoriatic arthritis; and chronic severe plaque psoriasis.

Renflexis: Merck

Renflexis is a prescription medicine that treats the following autoimmune diseases:

Crohn’s Disease (moderately to severely active): Can reduce signs and symptoms and induce and maintain remission in adult patients with moderately to severely active Crohn’s disease who haven’t responded well to other therapies

Pediatric Crohn’s Disease (moderately to severely active): Can reduce signs and symptoms and induce and maintain remission in children (ages 6-17) with moderately to severely active Crohn’s disease who haven’t responded well to other therapies

Ulcerative Colitis (moderately to severely active): Can reduce signs and symptoms, induce and maintain remission, promote intestinal healing, and reduce or stop the need for steroids in adult patients with moderately to severely active ulcerative colitis who haven’t responded well to other therapies

Pediatric Ulcerative Colitis (moderately to severely active): Can reduce signs and symptoms, induce and maintain remission, promote intestinal healing, and reduce or stop the need for steroids in children (ages 6-17) with moderately to severely active ulcerative colitis who haven’t responded well to other therapies

Infliximab Biosimilars: Emerging Drugs

BCD 055: Biocad

A biosimilar of infliximab, designated as BCD 055, is being developed by Biocad for the treatment of ankylosing spondylitis and rheumatoid arthritis.

CT-P17: Celltrion

Genor Biopharma (a subsidiary of Walvax Biotechnology) is developing a biosimilar of infliximab, designated as GB 242, for the treatment of Autoimmune disorders; Rheumatoid arthritis. The drug is currently in phase III stage of development.

Infliximab: Therapeutic Assessment

This segment of the report provides insights about the different Infliximab biosimilars segregated based on following parameters that define the scope of the report, such as:

Major Players in Infliximab

There are approx. 20+ key companies which are developing the therapies for Infliximab.

Phases

Infliximab pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Products have been categorized under various Molecule types such as

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Infliximab: Pipeline Development Activities

The report provides insights into different therapeutic candidates in marketed, phase III, II, I and preclinical stage. It also analyses Infliximab biosimilars drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Infliximab biosimilar drugs.

Report Highlights

Infliximab Biosimilars Report Insights

Infliximab Biosimilar Report Assessment

Key Questions

Current Treatment Scenario and Emerging Therapies:

Key Players

Key Products

For more information about this report visit https://www.researchandmarkets.com/r/8w4ril

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Exit mobile version